News

The 2025 Policy Address provides a powerful blueprint for Hong Kong's future as an international health and medical innovation hub, with a strategic focus on attracting companies to conduct clinical trials for rare diseases drugs, high-end cancer drugs, and advanced therapy products. 

Highlighting the strategic opportunity, Professor Bernard Cheung, CEO of GBAICTI, said, "GBAICTI welcomes the Policy Address, which puts innovation and technology high up on the agenda, particularly in the development of novel and advanced treatments of diseases. The Hong Kong SAR provides a unique platform for treatments developed in China to be marketed abroad, and to bring in the best treatments overseas to patients in Hong Kong and the rest of the Greater Bay Area.”

As the dedicated entity for clinical trials, GBAICTI is committed to enhancing the capacity and efficiency of clinical trials in Hong Kong and facilitating the translation of innovative biomedical researches into clinical applications. We will spearhead collaboration among key stakeholders, leveraging the unique advantages of Hong Kong to build a world-class ecosystem for medical innovation.